C1 Esterase Inhibitor (Human) (ViroPharma) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This C1 Esterase Inhibitor (Human) (ViroPharma) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
19
Registered trials
12
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether C1 Esterase Inhibitor (Human) (ViroPharma) can convert its Blood components profile and C1-INH biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | C1 Esterase Inhibitor (Human) (ViroPharma) (query alias: cinryze) |
|---|---|
| Modality / target | Blood components; C1-INH; C1-INH modulators |
| Highest global status | Approved |
| Originator | ViroPharma Biologics, Inc. |
| Active developers | Takeda Manufacturing Austria AG, Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals U.S.A., Inc. |
The MCP disease footprint includes Hereditary Angioedema, Aneurysm, Intracranial Berry, 1, Subarachnoid Hemorrhage. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT03051698 | Phase 4 | Terminated | 37 | Not disclosed |
| NCT02865720 | Phase 3 | Completed | 8 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) |
| NCT06359782 | Phase 2 | Recruiting | 128 | Number of participants with delayed cerebral ischemia (DCI) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Phase 3; n=39; evaluation: not stated. Reported fields: Percentage of Participants With New or Worsening Transplant Glomerulopathy (TG) at Month 6 Post-Treatment = 47.4 Percentage of participants ; Percentage of Participants With New or Worsening Transplant Glomerulopathy (TG) at Month 6 Post-Treatment: Difference in percentage = 2.6(95% CI, -29.4 to 34.5), P-Value = 0.6857; Percentage of Participants With New or Worsening Transplant Glomerulopathy (TG) at Month 6 Post-Treatment = 50.0 Percentage of participants
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
Phase 3; n=12; evaluation: Positive. Reported fields: Monthly NNA = 84.5 % ; Monthly NNA = 71.1 %
A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
Phase 3; n=8; evaluation: not stated. Reported fields: -; -; Number of Participants With Treatment-emergent Adverse Events (TEAEs) = 7 Participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
C1 Esterase Inhibitor (Human) (ViroPharma) addresses Hereditary Angioedema, Aneurysm, Intracranial Berry, 1, Subarachnoid Hemorrhage. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Blood components—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2013-11-11 | Shire to acquire ViroPharma in strategic move to strengthen rare disease portfolio; will augment already strong growth prospects | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “C1 Inhibitor Fusion Proteins and Uses Thereof”. The milestone feed surfaced a patent-application signal described as “C1-INH compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
